Association between Parathyroid Hormone Levels and Calcium–Phosphorus Balance in Hemodialysis Patients in Al Khums City, Libya
Keywords:
الفوسفور, الكالسيوم, غسيل الكلى, مرض الكلى المزمن, هرمون الغدة جار الدرقيةAbstract
Chronic kidney disease is a global health problem, often accompanied by disturbances in calcium and phosphorus balance and impaired parathyroid hormone regulation. Secondary hyperparathyroidism is common in dialysis patients, contributing to bone disorders and vascular calcification. This study was conducted at Al-Khums Kidney Hospital, Libya, from July to December 2024, involving 100 dialysis patients and 50 healthy individuals as a control group. Serum parathyroid hormone, calcium, and phosphorus levels were measured using biochemical methods. Patients showed significantly elevated parathyroid hormone (PTH) levels (567.52 ± 498.09 Pg/(mL)) and phosphorus levels (5.01 ± 1.90 mg/dL), and a marked decrease in calcium levels (7.40 ± 0.60 mg/dL) compared to the control group. Pearson correlations revealed a clear negative correlation between PTH and calcium, and a positive correlation between PTH and phosphorus. Elevated PTH levels in dialysis patients are closely associated with hypocalcemia and hyperphosphatemia, indicating mineral imbalances in chronic kidney disease and necessitating regular monitoring to prevent complications.
References
Block, G. A., Port, F. K., Pisoni, R. L., Locatelli, F., Held, P. J., & Chertow, G. M. (2004). Disorders of phosphorus and calcium in renal patients. American Journal of Kidney Diseases, 43(4), 576–585.
Evenepoel, P., Cunningham, J., Ferrari, S., Haarhaus, M., Javaid, M. K., Lafage-Proust, M. H., Prieto-Alhambra, D., Torres, P. U., & Cannata-Andía, J. (2021). Bone disease in chronic kidney disease: Pathophysiology and management. The Lancet Diabetes & Endocrinology, 9(9), 655–667.
Goodman, W. G., Quarles, L. D., & Hruska, K. A. (2004). Mineral metabolism disturbances in chronic kidney disease. Journal of the American Society of Nephrology, 15(6), 1642–1651.
Kazama, J. J., Matsuo, K., & Fukagawa, M. (2015). Calcium as a risk factor for progression of chronic kidney disease. Clinical and Experimental Nephrology, 19(6), 1024–1030.
Ketteler, M., Block, G. A., Evenepoel, P., Fukagawa, M., Herzog, C. A., McCann, L., & Moe, S. M. (2022). Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: Synopsis of the kidney disease: Improving Global Outcomes 2022 Clinical Practice Guideline Update. Annals of Internal Medicine, 177(1), 1–12.
Komaba, H., Hamano, T., Fujii, N., Moriwaki, K., Wada, A., Masakane, I., Nitta, K., & Fukagawa, M. (2023). The effects of parathyroidectomy vs medical treatments on survival in patients with severe secondary hyperparathyroidism undergoing hemodialysis. The Journal of Clinical Endocrinology & Metabolism, 108(2), 123–132.
Komaba, H., Hamano, T., Fujii, N., Moriwaki, K., Wada, A., Masakane, I., Nitta, K., & Fukagawa, M. (2022). Parathyroidectomy versus cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients. Journal of Clinical Endocrinology & Metabolism, 107(7), 2016–2025.
Lavin, A., Bakris, G. L., Molitch, M., Smulders, M., Tian, J., Williams, L. A., & Andress, D. L. (2007). Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney International, 71(1), 31–38.
Moe, S. M., & Drüeke, T. (2008). Management of secondary hyperparathyroidism: The importance of early intervention. Nephrology Dialysis Transplantation, 23(1), 9–12.
National Kidney Foundation. (2022). KDOQI clinical practice guideline for bone and mineral metabolism disorders in chronic kidney disease. American Journal of Kidney Diseases, 79(4 Suppl 1), S1–S107.
Palmer, S. C., Hayen, A., Macaskill, P., Pellegrini, F., Craig, J. C., Elder, G. J., & Strippoli, G. F. M. (2011). Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. Journal of the American Medical Association, 305(11), 1119–1127.
Wang, Y., Liu, X., Fang, X., Zhou, Y., Liu, Y., & Li, Y. (2024). Estimating the global prevalence of secondary hyperparathyroidism due to chronic kidney disease: A systematic review and meta-analysis. Frontiers in Endocrinology, 15, 1400891.
Zheng, C. M., Zheng, J. Q., Wu, C. C., Lu, K. C., & Chao, C. T. (2021). Role of vitamin D in chronic kidney disease From biological mechanisms to clinical benefits. Journal of Clinical Medicine, 10(8), 1805.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 آمنة عبد المطلب احريبش، يونس مفتاح الزائدي
This work is licensed under a Creative Commons Attribution 4.0 International License.
